Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
In these videos, Dr. Mansoor Mirza discusses how endometrial cancer treatment has changed in the past decade, adjuvant radiotherapy for patients with early-stage disease, current phase III trials of adjuvant radiotherapy with chemo, and adjuvant chemo alone, the molecular profile of endometrial cancers and how it pertains to immunotherapy, immunotherapy options for treating advanced or recurrent endometrial cancer, study results from first-line endometrial cancer studies, and key takeaways to point out when discussing the changing field of endometrial cancer treatment.
To watch the complete playlist, click here.
Please feel free to offer comments and raise questions in our
discussion forums.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.